p.82 抽出テキスト
Kusumoto et al 2018 Bradycardia Clinical Practice Guidelines Circulation. 2019;140:e382–e482. DOI: 10.1161/CIR.0000000000000628 August 20, 2019 e463 CLINICAL STATEMENTS AND GUIDELINES S5.3.2.4-47. Wenger TL. Experience with digoxin immune Fab (ovine) in patients with renal impairment. Am J Emerg Med. 1991;9:21–3; discussion 33–4. S5.3.2.4-48. Wenger TL, Butler VP Jr, Haber E, et al. Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. J Am Coll Cardiol. 1985;5:118a–23a. 5.3.3 Temporary Pacing for Bradycardia Attributable to SND S5.3.3-1. Hedges JR, Feero S, Shultz B, et al. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia. Pacing Clin Electrophysiol. 1991;14:1473–8. S5.3.3-2. Gallagher JJ, Smith WM, Kerr CR, et al. Esophageal pacing: a diagnostic and therapeutic tool. Circulation. 1982;65:336–41. S5.3.3-3. Smith I, Monk TG, White PF. Comparison of transesophageal atrial pacing with anticholinergic drugs for the treatment of intraoperative bradycardia. Anesth Analg. 1994;78:245–52. S5.3.3-4. López Ayerbe J, Villuendas Sabaté R, García García C, et al. Temporary pacemakers: current use and complications. Revista Española de Cardiología (English Edition). 2004;57:1045–52. S5.3.3-5. Ferguson JD, Banning AP, Bashir Y. Randomised trial of temporary cardiac pacing with semirigid and balloon-flotation electrode catheters. Lancet. 1997;349:1883. S5.3.3-6. Austin JL, Preis LK, Crampton RS, et al. Analysis of pacemaker malfunction and complications of temporary pacing in the coronary care unit. Am J Cardiol. 1982;49:301–6. S5.3.3-7. Betts TR. Regional survey of temporary transvenous pacing procedures and complications. Postgrad Med J. 2003;79:463–5. S5.3.3-8. Bjornstad CC, Gjertsen E, Thorup F, et al. Temporary cardiac pacemaker treatment in five Norwegian regional hospitals. Scand Cardiovasc J. 2012;46:137–43. S5.3.3-9. Garcia Guerrero JJ, Fernandez de la Concha Castaneda J, Lopez Quero D, et al. Lower incidence of venous thrombosis with temporary active-fixation lead implantation in mobile patients. Europace. 2010;12:1604–7. S5.3.3-10. Hynes JK, Holmes DR Jr, Harrison CE. Five-year experience with temporary pacemaker therapy in the coronary care unit. Mayo Clin Proc. 1983;58:122–6. S5.3.3-11. Jou YL, Hsu HP, Tuan TC, et al. Trends of temporary pacemaker implant and underlying disease substrate. Pacing Clin Electrophysiol. 2010;33:1475–84. S5.3.3-12. Jowett NI, Thompson DR, Pohl JE. Temporary transvenous cardiac pacing: 6 years experience in one coronary care unit. Postgrad Med J. 1989;65:211–5. S5.3.3-13. McCann P. A review of temporary cardiac pacing wires. Indian Pacing Electrophysiol J. 2007;7:40–9. S5.3.3-14. Muñoz Bono J, Prieto Palomino MA, Macías Guarasa I, et al. Efficacy and safety of non-permanent transvenous pacemaker implantation in an intensive care unit. Medicina Intensiva (English Edition). 2011;35:410–6. S5.3.3-15. Nolewajka AJ, Goddard MD, Brown TC. Temporary transvenous pacing and femoral vein thrombosis. Circulation. 1980;62:646–50. S5.3.3-16. Sodeck GH, Domanovits H, Meron G, et al. Compromising bradycardia: management in the emergency department. Resuscitation. 2007;73:96–102. S5.3.3-17. Weinstein J, Gnoj J, Mazzara JT, et al. Temporary transvenous pacing via the percutaneous femoral vein approach. A prospective study of 100 cases. Am Heart J. 1973;85:695–705. S5.3.3-18. Bektas F, Soyuncu S. The efficacy of transcutaneous cardiac pacing in. Am J Emerg Med. 2016;34:2090–3. S5.3.3-19. Clinton JE, Zoll PM, Zoll R, et al. Emergency noninvasive external cardiac pacing. J Emerg Med. 1985;2:155–62. S5.3.3-20. Morrison LJ, Long J, Vermeulen M, et al. A randomized controlled feasibility trial comparing safety and effectiveness of prehospital pacing versus conventional treatment: ‘PrePACE.’ Resuscitation. 2008;76:341–9. S5.3.3-21. Sherbino J, Verbeek PR, MacDonald RD, et al. Prehospital transcutaneous cardiac pacing for symptomatic bradycardia or bradyasystolic cardiac arrest: a systematic review. Resuscitation. 2006;70:193–200. S5.3.3-22. Zoll PM, Zoll RH, Falk RH, et al. External noninvasive temporary cardiac pacing: clinical trials. Circulation. 1985;71:937–44. S5.3.3-23. Murphy JJ. Current practice and complications of temporary trans- venous cardiac pacing. BMJ. 1996;312:1134. S5.3.3-24. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices). Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117:e350–408. S5.3.3-25. Silver MD, Goldschlager N. Temporary transvenous cardiac pacing in the critical care setting. Chest. 1988;93:607–13. S5.3.3-26. McLeod AA, Jokhi PP. Pacemaker induced ventricular fibrillation in coronary care units. BMJ. 2004;328:1249–50. S5.3.3-27. Braun MU, Rauwolf T, Bock M, et al. Percutaneous lead implantation connected to an external device in stimulation-dependent patients with systemic infection–a prospective and controlled study. Pacing Clin Electrophysiol. 2006;29:875–9. S5.3.3-28. Chauhan A, Grace AA, Newell SA, et al. Early complications after dual chamber versus single chamber pacemaker implantation. Pacing Clin Electrophysiol. 1994;17:2012–5. S5.3.3-29. Polyzos KA, Konstantelias AA, Falagas ME. Risk factors for cardiac implantable electronic device infection: a systematic review and meta-analysis. Europace. 2015;17:767–77. S5.3.3-30. Cummins RO, Graves JR, Larsen MP, et al. Out-of-hospital transcutaneous pacing by emergency medical technicians in patients with asystolic cardiac arrest. N Engl J Med. 1993;328:1377–82. S5.3.3-31. Im SH, Han MH, Kim SH, et al. Transcutaneous temporary car- diac pacing in carotid stenting: noninvasive prevention of angioplasty-induced bradycardia and hypotension. J Endovasc Ther. 2008;15:110–6. 5.4 Chronic Therapy/Management of Bradycardia Attributable to SND 5.4.1 General Principles of Chronic Therapy/ Management of Bradycardia Attributable to SND S5.4.1-1. Brodsky M, Wu D, Denes P, et al. Arrhythmias documented by 24 hour continuous electrocardiographic monitoring in 50 male medical students without apparent heart disease. Am J Cardiol. 1977;39:390–5. S5.4.1-2. Meytes I, Kaplinsky E, Yahini JH, et al. Wenckebach A-V block: a frequent feature following heavy physical training. Am Heart J. 1975;90:426–30. S5.4.1-3. Northcote RJ, Canning GP, Ballantyne D. Electrocardiographic findings in male veteran endurance athletes. Br Heart J. 1989;61:155–60. S5.4.1-4. Viitasalo MT, Kala R, Eisalo A. Ambulatory electrocardiographic recording in endurance athletes. Br Heart J. 1982;47:213–20. S5.4.1-5. Gadler F, Valzania C, Linde C. Current use of implantable electrical devices in Sweden: data from the Swedish pacemaker and implantable cardioverter-defibrillator registry. Europace. 2015;17:69–77. S5.4.1-6. Armaganijan LV, Toff WD, Nielsen JC, et al. Are elderly patients at increased risk of complications following pacemaker implantation? A meta-analysis of randomized trials. Pacing Clin Electrophysiol. 2012;35:131–4. S5.4.1-7. Kusumoto FM, Schoenfeld MH, Wilkoff BL, et al. 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extraction. Heart Rhythm. 2017;14:e503–51. S5.4.1-8. George KP, Wolfe LA, Burggraf GW. The ‘athletic heart syndrome’. A critical review. Sports Med. 1991;11:300–30. S5.4.1-9. Lee JZ, Ling J, Diehl NN, et al. Mortality and cerebrovascular events after heart rhythm disorder management procedures. Circulation. 2018;137:24–33. 5.4.2 Transient/Reversible Causes (Including Medications) of Bradycardia Attributable to SND S5.4.2-1. Sodeck GH, Domanovits H, Meron G, et al. Compromising brady- cardia: management in the emergency department. Resuscitation. 2007;73:96–102. Downloaded from http://ahajournals.org by on October 7, 2026